Sign up to save your podcasts
Or
Share Few & Far Between: How Biotech Gets Built
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Few & Far Between: How Biotech Gets Built
Few & Far Between: How Biotech Gets Built episodes
- Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.
"Try to find the people who have a really strong background in regulatory science, who really understand the fundamentals, and who you believe can think creatively about the challenges of the cell therapy space." - Chris Min, Longeveron
Biorasi welcomes Chris Min to the Few & Far Between podcast for an inside look at the cell therapy industry and the importance of finding the right team to support your clinical trials.
40 min - Episode 25: Jim Geraghty, Author and Biotech Industry Veteran
“We can’t take the orphan drug revolution for granted.“ Biorasi’s Few & Far Between Podcast welcomes Jim Geraghty, author and biotech industry veteran, to discuss the necessity and viability of orphan and rare disease research - for both patients and VC investors alike.
40 min - Episode 24: Gadi Lachman, President and CEO, TriNetX
Can data sharing make the world a better place? Listen in to the latest episode of Few & Far Between. Biorasi CEO, Chris O'Brien, welcomes Gadi Lachman, President and CEO of TriNetX, to discuss real-world solutions for accessing and refining patient data in the clinical trials industry.
40 min - Episode 23: Dr. Arun Bhatt, Consultant for Clinical Research and Drug Development in India
What makes India a smart and viable setting for today’s clinical trials? Join us for the latest episode of Few & Far Between. Biorasi's own Dr. Sagar Patil welcomes one of his early mentors, Dr. Arun Bhatt, for an in-depth discussion into the history and future of clinical research in India.
38 min - Episode 22: Dr. Jocelynn Pearl, Senior Scientist at Tune Therapeutics, Host of Lady Scientist Podcast
How can DAOs - Decentralized Autonomous Organizations - improve rare disease research? Biorasi's Few & Far Between Podcast welcomes Dr. Jocelynn Pearl, Senior Scientist at Tune Therapeutics and host of the Lady Scientist podcast, to discuss this new connection between clinical trials and cryptocurrency.
24 min - Episode 21: Jill Hawkins, Founder and President of the FAM177A1 Research Fund
How do you start in building a rare disease foundation? Biorasi's Few & Far Between Podcast Welcomes Jill Hawkins, Founder and President of the FAM177A1 Research Fund, to discuss the impact of an ultrarare disease on her family and the importance of moving forward towards awareness, support, and treatment.
37 min - Episode 20: Professor Bertil E. Lindmark MD, PhD, Author and CMO at Galecto, Inc.
What do the next 100 years have in store for healthcare and clinical research? Biorasi's Few & Far Between podcast welcomes Professor Bertil E. Lindmark MD, PhD, author and CMO at Galecto, Inc., for an in-depth discussion on the biological revolution and trends in the life sciences.
31 min - Episode 19: Leslie Michelson, Founder and CEO, Private Health Management
How do you obtain the best possible patient care available? On this week's Few & Far Between podcast, host Chris O'Brien welcomes patient advocacy innovator Leslie Michelson for a conversation on the importance of patient support, guidance, and healthcare accessibility.
37 min - Episode 18: Karen Petrou and David Brint - BioBonds
On this week’s Few & Far Between podcast episode, Biorasi’s CEO, Chris O'Brien, welcomes Karen Petrou and David Brint for an in-depth discussion on BioBonds and how they can jumpstart funding in clinical research for rare disease and other disorders.
56 min - Episode 17: Amy Fenton Parker, President and CEO at Batten Disease Support and Research Organization (BDSRA)
Why are advocacy and accessibility so important to rare diseases such as Batten Disease? On this week’s Few & Far Between podcast episode, Biorasi’s Becky Knockemus talks with Amy Fenton Parker, President and CEO at Batten Disease Support and Research Organization (BDSRA).
40 min
About Few & Far Between: How Biotech Gets Built
From the publisher's feed
Welcome to Few & Far Between! Melissa Alesse, President of Biorasi, is your host for fascinating conversations - from clinical research and policymakers to biotech innovators and industry leaders.